Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 4/20 | 0.62 |
| ▸ | ADORA2A | P29274 | 5/20 | 0.51 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.51 |
| ▸ | MAOB | P27338 | 3/20 | 0.51 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.51 |
| ▸ | LCK | P06239 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 2/20 | 0.47 |
| ▸ | CA1 | P00915 | 2/20 | 0.47 |
| ▸ | CA2 | P00918 | 2/20 | 0.47 |
| ▸ | CA9 | Q16790 | 2/20 | 0.47 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.47 |
| ▸ | TMIGD3 | P0DMS9 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11035657 | 0.86 | FLT3 (0.55) | MAOAADORA2AADORA1MAOBADORA3 | |
| SCHEMBL17724009 | 0.83 | MAOA (0.51) | MAOAMAOBCA12CA1CA2 | |
| SCHEMBL9990783 | 0.83 | MAOA (0.51) | MAOAADORA2AADORA1MAOBADORA3 | |
| SCHEMBL1896215 | 0.83 | LMNA (0.66) | MAOAADORA2AADORA1MAOBADORA3 | |
| SCHEMBL10509414 | 0.83 | ALDH1A1 (0.64) | MAOAADORA2AADORA1MAOBADORA3 | |
| SCHEMBL11752986 | 0.82 | NPC1 (0.67) | MAOAADORA2AADORA1MAOBADORA3 | |
| SCHEMBL2896177 | 0.81 | CA12 (0.47) | MAOACA12CA1CA2CA9 | |
| SCHEMBL2198159 | 0.81 | CHRNA7 (0.49) | MAOALMNARECQLKMT2AMEN1 | |
| SCHEMBL6237938 | 0.81 | DAO (0.48) | MAOALMNARECQLKMT2AMEN1 | |
| SCHEMBL2432723 | 0.81 | MAOB (0.53) | MAOAADORA2AADORA1MAOBADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8884020-B2 | Indole compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| US-8884020-B2 | Indole compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2610244-A1 | Indole compounds | Ironwood Pharmaceuticals, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| EP-2610244-A1 | Indole compounds | Ironwood Pharmaceuticals, Inc. (US) | 2013-07-03 | — | — | EP | disclosed |
| WO-2011159781-A2 | BITTER TASTE MODULATORS | SENOMYX, INC. (US) | 2011-12-22 | — | — | WO | disclosed |
| US-7960544-B2 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960544-B2 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960544-B2 | Useful indole compounds | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100197708-A1 | INDOLE COMPOUNDS | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2010-08-05 | — | — | US | disclosed |
| US-20100197708-A1 | INDOLE COMPOUNDS | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2010-08-05 | — | — | US | disclosed |
| WO-2004069133-A2 | N-MONOACYLATED O-PHENYLENEDIAMINES AS ANTI -CANCER AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-08-19 | — | — | WO | disclosed |
| US-20040157841-A1 | inhibition of histone deacetylase; for inhibiting cell proliferation; cancer therapy | HOFFMANN-LA ROCHE INC. | 2004-08-12 | — | — | US | disclosed |
| EP-1337513-A1 | 4-SUBSTITUTED QUINOLINES AS ANTITUMOR AGENTS | AstraZeneca AB (SE) | 2003-08-27 | — | — | EP | disclosed |
| WO-2002036570-A1 | 4-SUBSTITUTED QUINOLINES AS ANTITUMOR AGENTS | ASTRAZENECA AB (SE) | 2002-05-10 | — | — | WO | disclosed |
| EP-0187387-B1 | BENZOFURAN DERIVATIVE, PROCESS FOR PREPARING THE SAME AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | Kaken Pharmaceutical Co., Ltd. (JP) | 1988-09-28 | — | — | EP | disclosed |
| EP-0187387-A1 | Benzofuran derivative, process for preparing the same and pharmaceutical composition containing the same | Kaken Pharmaceutical Co., Ltd. (JP) | 1986-07-16 | — | — | EP | disclosed |
| US-4551468-A | INDOLE, BENZOFURANS, BENZOTHIOPHENES | PFIZER INC. (US) | 1985-11-05 | — | — | US | disclosed |
| EP-0050957-B1 | HETEROCYCLIC THROMBOXANE SYNTHETASE INHIBITORS, PROCESSES FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Pfizer Limited (GB) | 1984-08-22 | — | — | EP | disclosed |
| US-4410539-A | Heterocyclic thromboxane synthetase inhibitors and pharmaceutical compositions containing them | PFIZER INC. (US) | 1983-10-18 | — | — | US | disclosed |
| EP-0050957-A1 | Heterocyclic thromboxane synthetase inhibitors, processes for their preparation, and pharmaceutical compositions containing them | Pfizer Limited (GB) | 1982-05-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040157841-A1 | inhibition of histone deacetylase; for inhibiting cell proliferation; cancer therapy | HDAC1, HDAC11, HDAC7 | MAOA 229/4885ADORA2A 4494/4885ADORA1 3415/4885 |
| US-20100197708-A1 | INDOLE COMPOUNDS | IDO1, IDO2, TPH2 | MAOA 130/4885ADORA2A 213/4885ADORA1 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.